Delving into the Latest Updates on Beijing Increase Innovative Drug Research Co., Ltd. with Synapse

Overview

Tags

Respiratory Diseases

Herbal medicine

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Top 5 Drug Type	Count

Herbal medicine	1
Small molecule drug	1

1) Evaluate the safety and tolerability of single and multiple administrations of YKRH00020 inhalation solution to healthy subjects, determine the maximum tolerated dose (MTD), and provide a suitable administration dose (RP2D) for Phase II clinical trials. 2) Evaluate the pharmacokinetic characteristics of single and multiple administrations of YKRH00020 inhalation solution in healthy subjects.

Start Date24 Jul 2024

Sponsor / Collaborator

Shanghai Kaibao Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Beijing Increase Innovative Drug Research Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Increase Innovative Drug Research Co., Ltd.

Login to view more data

100 Deals associated with Beijing Increase Innovative Drug Research Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Increase Innovative Drug Research Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

1

Phase 1 Clinical

Login to view more data